Silicone-based fresh daily adhesive for comfort (can help reduce skin reactions)
Watch how Eversense helps Mateo get all the confidence, flexibility and peace of mind he needs to provide the attention his students deserve.
Short sensor life of 7-14 days
26-52 sensor changes per year
26-52 ‘Day 1’ warm-up periods
Need to self-insert the sensor
Transmitter must remain adhered to skin for sensor duration
Percutaneous sensor can be dislodged during everyday activities
Acrylate-based adhesives can cause skin
6-month sensor life
2 sensor changes per year
Only 2 ‘Day1’ warm up periods
Sensor insertion by a certified health care professional
Transmitter is removable** and provides unique on-body vibe alerts
Sensor stays put no matter what
Reduced irritation with gentle, silicone-based adhesive1
Multi-site prospective pivotal clinical trial of 180 type 1 and type 2 diabetes participants.
Accurate, Stable Performance up to 6 Months2
Percent of readings within 15 mg/dL or 15% of reference value
Proven high users acceptability
Reported improved confidence over control of their diabetes3
Reported less day-to-day burden3
were more motivated to keep up with diabetes management3
of users would choose to be inserted again3
Search our most commonly asked questions for quick answers.
Learn more about insurance coverage and eligibility.
*Up to 6 months
**There is no glucose data generated when the transmitter is removed
***The opinions expressed belong solely to the individual. This information provides general information only. It is not intended to be used as medical advice, diagnosis or treatment and should not replace the advice of a Health Care Provider
MARD is the mean absolute relative difference between sensor readings and matched reference values; the lower the MARD, the better the accuracy of the sensors being evaluated
1. Sanchez P, Ghosh-Dastidar S, Tweden K, Kaufman F. Real-World Data from the First US Commercial Users of an Implantable Continuous Glucose Sensor. Diabetes Technol Ther. Published online August 12, 2019, DOI:10.1089/dia.2019.0234.
2. Garg, S. K. et al. (2021). Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics, 24(2), 1–9. DOI: 10.1089/dia.2021.0182.
3. Barnard et al. Acceptability of Implantable Continuous Glucose Monitoring Sensor. Journal of Diabetes Science and Technology 2018, Vol. 12(3) 634–638.